Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib

Over the last several months, Pfizer has been putting together a profile of several Phase III trials for its experimental JAK1 inhibitor abrocitinib to take to regulators, in the hopes of taking down Dupixent. And on Wednesday, the big pharma released another set of positive topline data.